Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P08246

UPID:
ELNE_HUMAN

ALTERNATIVE NAMES:
Bone marrow serine protease; Elastase-2; Human leukocyte elastase; Medullasin; PMN elastase

ALTERNATIVE UPACC:
P08246; P09649; Q6B0D9; Q6LDP5

BACKGROUND:
The protein Neutrophil elastase, with alternative names such as Bone marrow serine protease and Human leukocyte elastase, is crucial for immune defense mechanisms. It inhibits C5a-dependent neutrophil enzyme release and chemotaxis and is capable of killing E.coli, indicating its significant role in pathogen defense. Its activity against outer membrane protein A in bacteria underscores its potential in antimicrobial strategies.

THERAPEUTIC SIGNIFICANCE:
Linked to disorders like Cyclic haematopoiesis and Severe congenital neutropenia 1, autosomal dominant, Neutrophil elastase's dysfunction highlights its therapeutic significance. Targeting Neutrophil elastase's pathways could lead to innovative treatments for these hematopoietic diseases, emphasizing the protein's critical role in advancing healthcare solutions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.